Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

United Therapeutics Corp

NASDAQ: UTHR · Life Sciences · 48 alerts · CIK 1082554

Share price
$587.88Close, Nov 16
Market cap
$25B
Shares outstanding
42.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All United Therapeutics Corp filings on SEC EDGAR ↗

4:30 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.18M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $531.92 to $550.72 a share (average $544.94) in 17 transactions, worth $5.18M in total on Oct 9, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.18M
Shares
9,500
Average price
$544.94
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Oct 9, 2026
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.08M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $525.50 to $541.23 a share (average $534.31) in 16 transactions, worth $5.08M in total on Oct 8, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.08M
Shares
9,500
Average price
$534.31
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 8, 2026
5:29 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.22M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $542.73 to $556.48 a share (average $548.95) in 14 transactions, worth $5.22M in total on Oct 7, 2026. Shares held after the trade: 326,883 (-0.1%).

Value
$5.22M
Shares
9,500
Average price
$548.95
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Oct 7, 2026
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.12M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $527.90 to $545.50 a share (average $538.67) in 17 transactions, worth $5.12M in total on Oct 6, 2026. Shares held after the trade: 331,171 (-0.0%).

Value
$5.12M
Shares
9,500
Average price
$538.67
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 6, 2026
4:32 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.15M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $536.26 to $546.63 a share (average $541.64) in 11 transactions, worth $5.15M in total on Oct 5, 2026. Shares held after the trade: 325,723 (-0.4%).

Value
$5.15M
Shares
9,500
Average price
$541.64
Role
Chairperson & CEO
Holding change
-0.4%
Trade date
Oct 5, 2026
4:53 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.22M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $542.06 to $574.23 a share (average $549.37) in 23 transactions, worth $5.22M in total on Oct 2, 2026. Shares held after the trade: 326,648 (-0.1%).

Value
$5.22M
Shares
9,500
Average price
$549.37
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Oct 2, 2026
4:32 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.48M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $560.05 to $584.66 a share (average $576.47) in 19 transactions, worth $5.48M in total on Oct 1, 2026. Shares held after the trade: 331,489 (-0.1%).

Value
$5.48M
Shares
9,500
Average price
$576.47
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Oct 1, 2026
5:30 PM ET Form 4
Insider Selling

United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.69M of Stock

Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $558.30 to $573.15 a share (average $564.95) in 10 transactions, worth $4.69M in total on Oct 1, 2026. Shares held after the trade: 45,332 (-1.8%).

Value
$4.69M
Shares
8,300
Average price
$564.95
Role
EVP & General Counsel
Holding change
-1.8%
Trade date
Oct 1, 2026
5:22 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.06M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 1,920 shares of United Therapeutics Corp at $547.29 to $554.70 a share (average $550.22) in 8 transactions, worth $1.06M in total on Sep 30, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$1.06M
Shares
1,920
Average price
$550.22
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Sep 30, 2026
5:21 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $3.93M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 7,580 shares of United Therapeutics Corp at $476.14 to $546.23 a share (average $517.97) in 24 transactions, worth $3.93M in total on Sep 30, 2026. Shares held after the trade: 331,103 (-0.0%).

Value
$3.93M
Shares
7,580
Average price
$517.97
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Sep 30, 2026
4:30 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.54M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $472.05 to $486.77 a share (average $477.42) in 12 transactions, worth $4.54M in total on Sep 29, 2026. Shares held after the trade: 325,263 (-0.0%).

Value
$4.54M
Shares
9,500
Average price
$477.42
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Sep 29, 2026
4:46 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.7M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $492.91 to $498.25 a share (average $494.79) in 6 transactions, worth $4.7M in total on Sep 18, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$4.7M
Shares
9,500
Average price
$494.79
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Sep 18, 2026
4:42 PM ET Form 4
Insider Selling

United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.13M of Stock

Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $495.97 to $501.58 a share (average $497.54) in 7 transactions, worth $4.13M in total on Sep 17, 2026. Shares held after the trade: 45,172 (-0.7%).

Value
$4.13M
Shares
8,300
Average price
$497.54
Role
EVP & General Counsel
Holding change
-0.7%
Trade date
Sep 17, 2026
4:42 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.71M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $493.22 to $501.60 a share (average $496.06) in 9 transactions, worth $4.71M in total on Sep 17, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$4.71M
Shares
9,500
Average price
$496.06
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Sep 17, 2026
4:36 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.77M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $499.77 to $504.57 a share (average $501.59) in 6 transactions, worth $4.77M in total on Sep 15, 2026. Shares held after the trade: 324,443 (-0.2%).

Value
$4.77M
Shares
9,500
Average price
$501.59
Role
Chairperson & CEO
Holding change
-0.2%
Trade date
Sep 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.